Arcus Biosciences/$RCUS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Arcus Biosciences

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Ticker

$RCUS
Sector

Primary listing

NYSE

Employees

627

RCUS Metrics

BasicAdvanced
$1.5B
-
-$3.07
0.89
-

What the Analysts think about RCUS

Analyst ratings (Buy, Hold, Sell) for Arcus Biosciences stock.

Bulls say / Bears say

Arcus ended Q2 2025 with $927 million in cash and marketable securities, providing funding runway through pivotal readouts for domvanalimab, casdatifan, and quemliclustat. (Nasdaq)
Interim data from the ARC-20 study showed a 46 percent confirmed overall response rate in metastatic clear cell renal cell carcinoma with casdatifan plus cabozantinib, supporting advancement into Phase 3 PEAK-1 and eVOLVE-RCC02 trials. (Arcus Press Release)
Quemliclustat received orphan drug designation from the U.S. FDA for pancreatic cancer, granting development incentives and up to seven years of market exclusivity as the registrational PRISM-1 Phase 3 trial progresses. (Arcus Press Release)
Q2 2025 revenue of $160 million was inflated by a one-time $143 million catch-up payment from Gilead’s return of the etrumadenant license, masking underlying operational performance. (Nasdaq)
Net cash used in operating activities doubled to $265 million for the six months ended June 30, 2025, signaling an accelerating cash burn that may pressure Arcus’s runway absent further non-dilutive financing. (Panabee)
Arcus paused development of etrumadenant after Gilead returned its license, reducing pipeline breadth and highlighting partner-related execution risk. (Arcus Press Release)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

RCUS Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RCUS Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RCUS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs